Drug industry CEOs angrily dispute Judge Matthew Kacsmaryk’s ruling on mifepristone. But they spent millions on the Senate Republicans who confirmed him.
prescription drugs
Posted inTAP
Resisting Kacsmaryk
Today on TAP: In Los Angeles, both the DA and the sheriff say there’ll be no arrests or prosecutions when women take abortion pills, regardless of court rulings.
Posted inLaw and Justice
Federal Judges Explain Things to Me
SCOTUS and Judge Kacsmaryk force us to pose the question: Where did it all go wrong?
Posted inHealth and Social Policy
India Decides Fighting Tuberculosis Is More Important Than Johnson & Johnson’s Profits
The country shot down a patent extension on a critical TB drug.
Posted inHealth and Social Policy
California Goes In for Drugmaking
The state will make and distribute insulin at cost. That should be a model for every other state.
Posted inTAP
A Big Miss on Drug Prices
Today on Tap: President Biden’s NIH rejects a petition to seize the patent of an unaffordable prescription drug.
Posted inPolitics
The American Rescue Plan’s Hidden Triumphs
Medicaid expansion in North Carolina and Eli Lilly’s insulin price cuts are largely due to the March 2021 law.
Posted inTAP
A Small Victory Over Big Pharma
Today on TAP: Eli Lilly announces insulin price caps, but keep an eye on the footnotes.
Posted inHealth and Social Policy
Private Health Care Companies Are Eating the American Economy
A new report from Wendell Potter at the Center for Health and Democracy examines just how the private insurance market makes its money—and how American health care is worse off for it.
Posted inEconomic Policy
Breaking Up (With China) Is Hard to Do
In the absence of more attention to the supply chain, the U.S. is becoming even more reliant on Beijing—and ‘friendshoring’ often increases that dependence.
